INBRAIN Neuroelectronics, a spin-off licensing and clinically translating technologies from our collaboration with ICN2 and other partners of the Graphene Flagship project, was established with the mission to develop brain-implants based on graphene technology for application in patients with epilepsy, Parkinson’s, and other neurological diseases. These smart devices, built around an innovative graphene electrode, will decode with high fidelity neural signals from the brain and produce a therapeutic response adapted to the clinical condition of the specific patient.  

The Graphene Flagship, one of Europe’s biggest-ever research initiatives, has highlighted this spin-off on its website. According to the Flagship, INBRAIN is currently working to ensure patient safety and to comply with necessary preclinical work and clinical regulatory milestones. The first-in-human-studies have started in collaboration with the University of Manchester and NHS Salford Royal.